June 20, 2017 10:03 AM EDTUpdated 11:12 AM
News Briefing

In wake of a tri­al dis­as­ter, Seat­tle Ge­net­ics files sBLA; Egalet takes a dive on a CRL

Emma Yasinski

→ One day af­ter scrap­ping a Phase III study, Seat­tle Ge­net­ics filed an sBLA for Ad­cetris to treat pa­tients with cu­ta­neous T-cell lym­phoma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Wal­greens in talks to sell to pri­vate eq­ui­ty — re­port

Roche ini­tial­ly did­n't want to buy Po­sei­da — and part­ner Astel­las did­n't sub­mit an of­fer, new fil­ings show

New on­col­o­gy biotech launch­es with $52M in its pock­et

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times